Bridgefront Capital, LLC Immunovant, Inc. Transaction History
Bridgefront Capital, LLC
- $331 Million
- Q1 2025
A detailed history of Bridgefront Capital, LLC transactions in Immunovant, Inc. stock. As of the latest transaction made, Bridgefront Capital, LLC holds 36,059 shares of IMVT stock, worth $991,983. This represents 0.3% of its overall portfolio holdings.
Number of Shares
36,059Holding current value
$991,983% of portfolio
0.3%Shares
5 transactions
Others Institutions Holding IMVT
# of Institutions
226Shares Held
78.6MCall Options Held
1.5MPut Options Held
1.55M-
Deep Track Capital, LP Greenwich, CT9.5MShares$261 Million9.14% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.94MShares$191 Million0.0% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.89MShares$162 Million0.07% of portfolio
-
Baker Bros. Advisors LP New York, NY5.46MShares$150 Million1.79% of portfolio
-
Black Rock Inc. New York, NY4.92MShares$135 Million0.0% of portfolio
About Immunovant, Inc.
- Ticker IMVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 129,077,000
- Market Cap $3.55B
- Description
- Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...